Brain

Alpha Tau Announces Receipt of Radioactive Material License for its New Hampshire Manufacturing Facility, Advancing Towards Commercial Readiness

- Receipt of critical license marks significant milestone for first commercial-scale manufacturing facility for Alpha DaRT®, the innovative alpha-radiation cancer therapy...

Nxera’s Partner Cancer Research UK Presents Data from Successfully Completed Phase 1 Clinical Trial of Cancer Immunotherapy Drug HTL0039732 at ESMO

HTL0039732 (also known as NXE0039732) is Nxera’s novel oral EP4 antagonist with the potential to treat a wide range of...

The Jackson Laboratory acquires New York Stem Cell Foundation to transform biomedical research and accelerate precision therapies for patients

New integrated platform will transform early-stage research, equipping scientists worldwide to uncover disease mechanisms earlier and advance progress toward therapies...

ExaCare AI Raises $30M Series A to Reimagine Admissions and Launch a Powerful Suite of AI Agents for Skilled Nursing & Home Care

Insight Partners-led funding will accelerate ExaCare AI's development of intelligent decisioning, clinical insight, reimbursement automation, and go-to-market expansion; ExaCare AI...

MIRA Pharmaceuticals Announces Oral Mira-55 Outperformed Injected Morphine in Normalizing Pain and Reducing Inflammation, Supporting Its Planned IND for Chronic Inflammatory Pain

Findings show oral Mira-55 fully normalized pain and significantly reduced inflammation, supporting IND plans and reinforcing MIRA's position in a...

error: Content is protected !!